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Abstract
Background ‘Mapping’ onto generic preference-based
outcome measures is increasingly being used as a means of
generating health utilities for use within health economic
evaluations. Despite publication of technical guides for the
conduct of mapping research, guidance for the reporting of
mapping studies is currently lacking. The MAPS (MAp-
ping onto Preference-based measures reporting Standards)
statement is a new checklist, which aims to promote
complete and transparent reporting of mapping studies.
Methods In the absence of previously published reporting
checklists or reporting guidance documents, a de novo list
of reporting items was created by a working group com-
prising six health economists and one Delphi methodolo-
gist. A two-round, modified Delphi survey, with
representatives from academia, consultancy, health tech-
nology assessment agencies and the biomedical journal
editorial community, was used to identify a list of essential
reporting items from this larger list.
Results From the initial de novo list of 29 candidate
items, a set of 23 essential reporting items was developed.
The items are presented numerically and categorized
within six sections: (1) title and abstract; (2) introduction;
(3) methods; (4) results; (5) discussion; and (6) other. The
MAPS statement is best applied in conjunction with the
accompanying MAPS Explanation and Elaboration paper.
Conclusion It is anticipated that the MAPS statement will
improve the clarity, transparency and completeness of the
reporting of mapping studies. To facilitate dissemination
and uptake, the MAPS statement is being co-published by
seven health economics and quality-of-life journals, and
broader endorsement is encouraged. The MAPS working
group plans to assess the need for an update of the
reporting checklist in 5 years’ time.
1 Introduction
The process of ‘mapping’ onto generic preference-based
outcome measures is increasingly being used as a means of
generating health utilities for application within health
economic evaluations [1]. Mapping involves the develop-
ment and use of an algorithm (or algorithms) to predict the
primary outputs of generic preference-based outcome
measures, i.e. health utility values, using data on other
indicators or measures of health. The source predictive
measure may be a non-preference-based indicator or
measure of health outcome or, more exceptionally, a
preference-based outcome measure that is not preferred by
the local health technology assessment agency. The algo-
rithm(s) can subsequently be applied to data from clinical
trials, observational studies or economic models containing
the source predictive measure(s) to predict health utility
values in contexts where the target generic preference-
based measure is absent. The predicted health utility values
can then be analysed using standard methods for
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individual-level data (e.g. within a trial-based economic
evaluation) or summarized for each health state within a
decision-analytic model.
Over recent years, there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values, and databases of published studies
in this field are beginning to emerge [2]. Some authors [3]
and agencies [4] concerned with technology appraisals
have issued technical guides for the conduct of mapping
research. However, guidance for the reporting of mapping
studies is currently lacking. In keeping with health-related
research more broadly [5], mapping studies should be
reported fully and transparently to allow readers to assess
the relative merits of the investigation [6]. Moreover, there
may be significant opportunity costs associated with reg-
ulatory and reimbursement decisions for new technologies
informed by misleading findings from mapping studies.
This has led to the development of the MAPS (MApping
onto Preference-based measures reporting Standards)
reporting statement, which we summarize in this paper.
The aim of the MAPS reporting statement is to provide
recommendations in the form of a checklist of essential
items that authors should consider when reporting a map-
ping study. It is anticipated that the checklist will promote
complete and transparent reporting by researchers. The
focus, therefore, is on promoting the quality of the
reporting of mapping studies, rather than the quality of
their conduct, although it is possible that the reporting
statement will also indirectly enhance the methodological
rigour of the research [7]. The MAPS reporting statement is
primarily targeted at researchers developing mapping
algorithms, the funders of the research, and peer reviewers
and editors involved in the manuscript review process for
mapping studies [5, 6]. In developing the reporting state-
ment, the term ‘mapping’ is used to cover all approaches
that predict the outputs of generic preference-based out-
come measures using data on other indicators or measures
of health, and encompasses related forms of nomenclature
used by some researchers, such as ‘cross-walking’ or
‘transfer to utility’ [1, 8]. Similarly, the term ‘algorithm’ is
used in its broadest sense to encompass statistical associ-
ations and more complex series of operations.
2 The Development of the MAPS Statement
The development of the MAPS reporting statement was
informed by recently published guidance for health
research reporting guidelines [5] and broadly modelled
other recent reporting guideline developments [9–14]. A
working group comprising six health economists (SP,
ORA, HD, LL, MO, AG) and one Delphi methodologist
(RF) was formed following a request from an academic
journal to develop a reporting statement for mapping
studies. One of the working group members (HD) had
previously conducted a systematic review of studies map-
ping from clinical or health-related quality-of-life measures
onto the EQ-5D [2]. Using the search terms from this
systematic review, as well as other relevant articles and
reports already in our possession, a broad search for
reporting guidelines for mapping studies was conducted.
This confirmed that no previous reporting guidance had
been published. The working group members therefore
developed a preliminary de novo list of 29 reporting items
and accompanying explanations. Following further review
by the working group members, this was subsequently
distilled into a list of 25 reporting items and accompanying
explanations.
Members of the working group identified 62 possible
candidates for a Delphi panel from a pool of active
researchers and stakeholders in this field. The candidates
included individuals from academic and consultancy set-
tings with considerable experience in mapping research,
representatives from health technology assessment agen-
cies that routinely appraise evidence informed by mapping
studies, and biomedical journal editors. Health economists
from the MAPS working group were included in the Delphi
panel. A total of 48 of the 62 individuals (77.4 %) agreed
to participate in a Delphi survey aimed at developing a
minimum set of standard reporting requirements for map-
ping studies, with an accompanying reporting checklist.
The Delphi panellists were sent a personalized link to a
Web-based survey, which had been piloted by members of
the working group. Non-responders were sent up to two
reminders after 14 and 21 days. The panellists were
anonymous to each other throughout the study, and their
identities were known only to one member of the working
group. The panellists were invited to rate the importance of
each of the 25 candidate reporting items identified by the
working group on a 9-point rating scale [from 1 (‘not
important’) to 9 (‘extremely important’)]; describe their
confidence in their ratings (‘not confident’, ‘somewhat
confident’ or ‘very confident’); comment on the candidate
items and their explanations; suggest additional items for
consideration by the panellists in subsequent rounds; and
provide any other general comments. The candidate
reporting items were ordered within six sections: (1) title
and abstract; (2) introduction; (3) methods; (4) results; (5)
discussion; and (6) other. The panellists also provided
information about their geographical area of work, gender,
and primary and additional work environments. The data
were imported into Stata software (version 13; StataCorp.,
College Station, TX, USA) for analysis.
A modified version of the Research ANd Development
(RAND)/University of California Los Angeles (UCLA)
appropriateness method was used to analyse the round 1
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responses [15]. This involved calculating the median score,
the inter-percentile range (IPR) [30th and 70th], and the
inter-percentile range adjusted for symmetry (IPRAS), for
each item (i) being rated. The IPRAS includes a correction
factor for asymmetric ratings, and panel disagreement was
judged to be present in cases if IPRi[ IPRASi [15]. We
modified the RAND/UCLA approach by asking panellists
about ‘importance’ rather than ‘appropriateness’ per se.
Assessment of importance followed the classic RAND/
UCLA definitions, categorized simply as whether the
median rating fell between 1 and 3 (unimportant), between
4 and 6 (neither unimportant nor important) or between 7
and 9 (important) [15].
The results of round 1 of the Delphi survey were reviewed
at a face-to-face meeting of the working group. A total of 46
of the 48 individuals (95.8 %) who agreed to participate
completed round 1 of the survey. Of the 25 items, 24 were
rated as important, with one item (‘Source of Funding’)
being rated as neither unimportant nor important. There was
no evidence of disagreement on ratings of any items
according to the RAND/UCLA method. These findings did
not change when the responses of the MAPS working group
were excluded. On the basis of the qualitative feedback
received in round 1, items describing ‘Modelling Approa-
ches’ and ‘Repeated Measurements’ were merged, as were
items describing ‘Model Diagnostics’ and ‘Model Plausi-
bility’. In addition, amendments to the wording of several
recommendations and their explanations were made in the
light of qualitative feedback from the panellists.
Panellists participating in round 1 were invited to par-
ticipate in a second round of the Delphi survey. A summary
of revisions made following round 1 was provided. This
included a document in which revisions of each of the
recommendations and explanations were displayed in the
form of tracked changes. Panellists participating in round 2
were provided with group outputs (mean scores and their
standard deviations, median scores and their IPRs, his-
tograms and RAND/UCLA labels of importance and
agreement level) summarizing the round 1 results (and
disaggregated outputs for the merged items). They were
also able to view their own round 1 scores for each item
(and disaggregated scores for the merged items). Panellists
participating in round 2 were offered the opportunity to
revise their rating of the importance of each of the items
and informed that their rating from round 1 would other-
wise hold. For the merged items, new ratings were soli-
cited. Panellists participating in round 2 were also offered
the opportunity to provide any further comments on each
item or any further information that might be helpful to the
group. Non-responders to the second round of the Delphi
survey were sent up to two reminders after 14 and 21 days.
The analytical methods for the round 2 data mirrored those
for the first round.
The results of the second round of the Delphi survey
were reviewed at a face-to-face meeting of the working
group. A total of 39 of the 46 panellists (84.8 %) partici-
pating in round 1 completed round 2 of the survey. All 23
items included in the second round were rated as important,
with no evidence of disagreement on ratings of any items
according to the RAND/UCLA method. Qualitative feed-
back from the panellists participating in round 2 led to
minor modifications of the wording of a small number of
recommendations and their explanations. This was fed
back to the round 2 respondents, who were given a final
opportunity to comment on the readability of the final set of
recommendations and explanations. On the basis of these
methods, a final consensus list of 23 reporting items was
developed.
3 The MAPS Statement
The MAPS statement is a 23-item checklist of recom-
mendations (Table 1) that we consider essential for com-
plete and transparent reporting of studies that map onto
generic preference-based outcome measures. The 23
reporting items are presented numerically and categorized
within six sections: (1) title and abstract (2 items); (2)
introduction (2 items); (3) methods (9 items); (4) results (6
items); (5) discussion (3 items); and (6) other (1 item). The
reporting of each item does not necessarily have to follow
the order within the MAPS statement. Rather, what is
important is that each recommendation is addressed either
in the main body of the report or in its appendices. Several
biomedical journals have endorsed the MAPS statement.
These include Applied Health Economics and Health
Policy, Health and Quality of Life Outcomes, International
Journal of Technology Assessment in Health Care, Journal
of Medical Economics, Medical Decision Making, Phar-
macoEconomics and Quality of Life Research. We
encourage other journals and research interest groups to
endorse the MAPS statement, and we encourage authors to
adhere to its principles.
4 The MAPS Explanation and Elaboration Paper
In addition to the MAPS reporting statement, we have
produced a supporting Explanation and Elaboration paper
[16] modelled on those developed for other reporting
guidelines [9–14]. The reporting items contained within the
MAPS statement are best understood by referring to the
information contained within this accompanying docu-
ment. The Explanation and Elaboration paper provides
exemplars of good reporting practice identified from the
published literature for each reporting item. In addition, it
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures
Table 1 Checklist of items to include when reporting a mapping study
Section/topic Item
number
Recommendation Reported on page
number/line
number
Title and abstract
Title 1 Identify the report as a study mapping between outcome
measures. State the source measure(s) and generic, preference-
based target measure(s) used in the study
________________
Abstract 2 Provide a structured abstract including, as applicable, objectives;
methods, including data sources and their key characteristics,
outcome measures used and estimation and validation
strategies; results, including indicators of model performance;
conclusions; and implications of key findings
________________
Introduction
Study rationale 3 Describe the rationale for the mapping study in the context of the
broader evidence base
________________
Study objective 4 Specify the research question with reference to the source and
target measures used and the disease or population context of
the study
________________
Methods
Estimation sample 5 Describe how the estimation sample was identified, why it was
selected, the methods of recruitment and data collection, and its
location(s) or setting(s)
________________
External validation sample 6 If an external validation sample was used, the rationale for
selection, the methods of recruitment and data collection, and its
location(s) or setting(s) should be described
________________
Source and target measures 7 Describe the source and target measures and the methods by
which they were applied in the mapping study
________________
Exploratory data analysis 8 Describe the methods used to assess the degree of conceptual
overlap between the source and target measures
________________
Missing data 9 State how many data were missing and how missing data were
handled in the sample(s) used for the analyses
________________
Modelling approaches 10 Describe and justify the statistical model(s) used to develop the
mapping algorithm
________________
Estimation of predicted scores or utilities 11 Describe how predicted scores or utilities are estimated for each
model specification
________________
Validation methods 12 Describe and justify the methods used to validate the mapping
algorithm
________________
Measures of model performance 13 State and justify the measure(s) of model performance that
determine the choice of the preferred model(s) and describe how
these measures were estimated and applied
________________
Results
Final sample size(s) 14 State the size of the estimation sample and any validation
sample(s) used in the analyses (including both number of
individuals and number of observations)
________________
Descriptive information 15 Describe the characteristics of individuals in the sample(s) (or
refer back to previous publications giving such information).
Provide summary scores for source and target measures, and
summarize results of analyses used to assess overlap between
the source and target measures
________________
Model selection 16 State which model(s) is(are) preferred and justify why this(these)
model(s) was(were) chosen
________________
Model coefficients 17 Provide all model coefficients and standard errors for the selected
model(s). Provide clear guidance on how a user can calculate
utility scores based on the outputs of the selected model(s)
________________
Uncertainty 18 Report information that enables users to estimate standard errors
around mean utility predictions and individual-level variability
________________
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provides a detailed explanation to accompany each rec-
ommendation, supported by a rationale and relevant evi-
dence where available. The development of the
Explanation and Elaboration paper was completed fol-
lowing several iterations produced by members of the
working group, after which the examples and explanations
were shared with the Delphi panellists for final revisions to
improve readability, and for their approval. The Explana-
tion and Elaboration paper also summarizes the charac-
teristics of the Delphi panellists and provides detailed
statistics for item ratings at each Delphi round.
5 Discussion
Over recent years, there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values. One recent review article identi-
fied 90 studies, published up to the year 2013, reporting
121 mapping algorithms between clinical or health-related
quality-of-life measures and the EQ-5D [2]. That review
article excluded mapping algorithms targeted at other
generic preference-based outcome measures that can gen-
erate health utilities, such as the SF-6D [17] and the Health
Utilities Index (HUI) [18], which have been the target of
numerous other mapping algorithms (e.g. [1, 19–24]).
Moreover, the popularity of the mapping approach for
estimating health utilities is unlikely to wane, given the
numerous contexts within health economic evaluation
where primary data collection is challenging. However,
mapping introduces additional uncertainty, and collection
of primary data with the preferred utility instrument is
preferable.
The MAPS reporting statement was developed to pro-
vide recommendations, in the form of a checklist of
essential items, that authors should consider when report-
ing mapping studies. Guidance for the reporting of map-
ping studies was not previously available in the literature.
The overall aim of MAPS is to promote clarity, trans-
parency and completeness of the reporting of mapping
studies. It is not intended to act as a methodological guide,
nor as a tool for assessing the quality of study methodol-
ogy. Rather, it aims to avoid misleading conclusions being
drawn by readers, and ultimately policy makers, as a result
of suboptimal reporting. In keeping with other recent health
research reporting guidelines, we have also produced an
accompanying Explanation and Elaboration paper [16] to
facilitate a deeper understanding of the 23 items contained
within the MAPS reporting statement. That paper should
hopefully act as a pedagogical framework for researchers
reporting mapping studies.
The development of the MAPS reporting statement, and
of its Explanation and Elaboration paper, was framed by
recently published guidance for health research reporting
guidelines [5]. The Delphi panel was composed of a multi-
disciplinary, multi-national team of content experts and
journal editors. The panel members included people
experienced in conducting mapping studies; of the 84
researchers who were first authors on papers included in a
recent review of EQ-5D mapping studies [2], 31 (36.9 %)
Table 1 continued
Section/topic Item
number
Recommendation Reported on page
number/line
number
Model performance and face validity 19 Present results of model performance, such as measures of
prediction accuracy and fit statistics for the selected model(s) in
a table or in the text. Provide an assessment of face validity of
the selected model(s)
________________
Discussion
Comparisons with previous studies 20 Report details of previously published studies developing
mapping algorithms between the same source and target
measures and describe differences between the algorithms, in
terms of model performance, predictions and coefficients, if
applicable
________________
Study limitations 21 Outline the potential limitations of the mapping algorithm ________________
Scope of applications 22 Outline the clinical and research settings in which the mapping
algorithm could be used
________________
Other
Additional information 23 Describe the source(s) of funding and non-monetary support for
the study, and the role of the funder(s) in its design, conduct and
report. Report any conflicts of interest surrounding the roles of
authors and funders
________________
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were included as panellists. We have no evidence to
believe that a larger panel would have altered the final set
of recommendations. The Delphi methodologies that we
applied included analytical approaches only recently
adopted by developers of health reporting guidelines [15].
We are unable to assess whether strict adherence to the
MAPS checklist will increase the word counts of mapping
reports. It is our view that the increasing use of online
appendices by journals should permit comprehensive
reporting even in the context of strict word limits for the
main body of reports.
Evidence for other health research reporting guidelines
suggests that the reporting quality has improved after the
introduction of reporting checklists [25–27], although there
is currently no empirical evidence that adoption of MAPS
will improve the quality of reporting of mapping research.
Future research planned by the MAPS working group will
include a before-and-after evaluation of the benefits (and,
indeed, possible adverse effects) of the introduction of the
MAPS reporting statement. It will also be necessary to
update the MAPS reporting statement in the future to
address conceptual, methodological and practical advances
in the field. Potential methodological advances that might
be reflected in an update might include shifts towards more
complex model specifications, better methods for dealing
with uncertainty, and guidance on appropriate use of
measures of prediction accuracy, such as the mean absolute
error (MAE) and the mean squared error (MSE). The
MAPS working group plans to assess the need for an
update of the reporting checklist in 5 years’ time.
6 Conclusion
This paper summarizes a new reporting statement devel-
oped for studies that map onto generic preference-based
outcome measures. We encourage health economic and
quality-of-life journals to endorse MAPS, promote its use
in peer review and update their editorial requirements and
‘Instructions to Authors’ accordingly.
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